CompletedNot Applicable

The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma

China68 participantsStarted 2021-01-01

Plain-language summary

This project will target patients with histopathologically diagnosed mucosal melanoma using \[¹⁸F\]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of \[¹⁸F\]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations between quantitative \[¹⁸F\]FDG PET parameters and progression-free survival (PFS) as well as overall survival (OS), so as to provide reference evidence for individualized treatment decision-making.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with histopathologically confirmed mucosal melanoma.

Exclusion criteria

✕. Having another primary malignancy (other than mucosal melanoma).
✕. Being lost to follow-up.
✕. Being under 18 years of age.
✕. Being pregnant or breastfeeding.

What they're measuring

Overall survival

Timeframe: Up to 4 years

Progression-free survival

Timeframe: Up to 4 years

Trial details

NCT IDNCT07506447

SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-05-08

View on ClinicalTrials.gov More FDG PET trials